Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Leukemia, Myeloid, Acute 3Sezary Syndrome 2Mycosis Fungoides 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

devimistat 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × C04.588.274.476.411.307 × devimistat × Clear all
NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Cornerstone Pharmaceuticals

Phase 1 Withdrawn

C04.588.274.476.411.307

Data powered by HemOnc (CC BY 4.0) Colophon âš¡